Inhibition of these receptors, especially when combined with tumor vaccines or anti–PD-1, has been shown to increase IFN-γ and IL-12 production, supporting a pro-inflammatory tumor microenvironment (157, 161, 162). The gene discussed is IFNG; the disease is neoplasm.